MolNFT v1 · #25082 · protein
CGSTA1-1 in complex with glutathione conjugate of cdnb
1VF3 · Glutathione S-transferase 3: “CGSTA1-1 in complex with glutathione conjugate of cdnb”. X-ray diffraction, 1 ligand (GDN), 6 pockets (best druggability 0.80). MolNFT v1 #25082 on GenesisL1: 3D structure, binding sites and pockets in…
- PDB
- 1VF3
- Type
- protein
- Length
- 450 residues
- Chains
- 2
- Method
- x-ray diffraction
- Collection
- MolNFT v1 / PDB
- Contract
- 0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
- Owner
- 0x3396CDB397284571d12822B4ae1189a8E22AAAAA
- Molecule
- Glutathione S-transferase 3
- EC
- 2.5.1.18
- UniProt
- P26697
- Ligands
- GDN
- Pockets
- 6 · best druggability 0.80
Structure
x-ray diffraction · 1 distinct chain · 58% helix, 7% strand (DSSP).
| Chain | Molecule | Type | Residues | Secondary structure | UniProt |
|---|---|---|---|---|---|
| A, B | Glutathione S-transferase 3 (EC 2.5.1.18) | protein | 225 | 58% helix, 7% strand | P26697 |
Ligands and binding sites
- GDN · Glutathione S-(2,4 dinitrobenzene) · ligand · 2 copies · chains A, B
- ACY · Acetic acid · additive · chains A
Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.
Pockets
6 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.
| Volume (ų) | Druggability | Buriedness | Lining residues | Inside | |
|---|---|---|---|---|---|
| 1 | 1066 | 0.80 | 0.81 | 108 | GDN |
| 2 | 143 | 0.41 | 0.74 | 25 | empty |
| 3 | 134 | 0.40 | 0.74 | 19 | empty |
| 4 | 128 | 0.39 | 0.74 | 21 | empty |
| 5 | 74 | 0.38 | 0.78 | 12 | empty |
Interfaces
1 interface between chains.
- A–B · 1508 Ų buried · 23 hydrogen bonds · protein-protein
Compared structures
Analyse
- Open in the research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides and crosslinks on the 3D structure
- Every structure of UniProt P26697
- Elsewhere: RCSB PDB 1VF3 · PDBe 1VF3 · UniProt P26697
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.